Insys Therapeutics Inc (INSY) : Mizuho Securities Usa added new position in Insys Therapeutics Inc during the most recent quarter end. The investment management firm now holds 9,000 shares of Insys Therapeutics Inc which is valued at $145,080 , the company said in a statement filed on Apr 21, 2016 with the SEC.Insys Therapeutics Inc makes up approximately 0.04% of Mizuho Securities Usa’s portfolio.
Insys Therapeutics Inc closed down -0.88 points or -5.71% at $14.52 with 4,12,652 shares getting traded on Wednesday. Post opening the session at $15.19, the shares hit an intraday low of $14.51 and an intraday high of $15.5281 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Strs Ohio sold out all of its stake in INSY during the most recent quarter. The investment firm sold 430,000 shares of INSY which is valued $6,931,600. Wunderlich Securities sold out all of its stake in INSY during the most recent quarter. The investment firm sold 7,400 shares of INSY which is valued $105,968.
On the company’s financial health, Insys Therapeutics Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Feb 23, 2016. Analyst had a consensus of $0.29. The company had revenue of $91.10 million for the quarter, compared to analysts expectations of $91.04 million. The company’s revenue was up 37.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Insys Therapeutics Inc. Shares were Reiterated by Jefferies on Apr 12, 2016 to “Buy” and Lowered the Price Target to $ 17 from a previous price target of $23 .Shares were Reiterated by Piper Jaffray on Apr 11, 2016 to “Overweight” and Lowered the Price Target to $ 28 from a previous price target of $46 .Shares were Reiterated by Jefferies on Feb 24, 2016 to “Buy” and Lowered the Price Target to $ 23 from a previous price target of $36 .
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.